March
7,
2007 -- 6:02am EST
And The Winner Is...
Word on the street is that the FDA
is planning to announce labeling changes for drug-eluting stents
later
today,
during the CRT
2007 meeting in Washington. These changes
have been anticipated ever since the FDA held its panel on stent
safety
back
on
December 7-8 and many recommendations were heard.
This announcement has not been confirmed but, since
I didn't get enough of the Oscars this year, I thought I'd
take a shot at predicting the winners (from those nominated at
the December panel).
For Best Picture: Extended Antiplatelet Therapy.
Currently dual antiplatelet therapy (aspirin plus clopidogrel/Plavix
or ticlopidine/Ticlid) extends for 3 months (Cypher) or 6 months
(Taxus). I'll bet on a recommendation of 12 months for
patients with low risk of bleeding complications. This change is
clearly the
front-runner, having previously been
recommended by all major cardiology and surgical organizations
in January's Joint
Science Advisory (a.k.a. The Golden Globes).
Best Director will be, I think, a caution to
prescribing physicians to consider a bare-metal stent in
patients who, for economic, clinical or other reasons, have a high
likelihood of non-compliance with antiplatelet therapy or who are
going to be needing surgical procedures which will require cessation
of antiplatelet therapy. This one has gotten the clear recommendation
of several groups as well. The question is whether it will become
part of the label.
Finally for Best Actor/Actress, I vote for the "off label" label -- some
language that advises prescribing physicians that the results and
benefits of DES that have been demonstrated in clinical
trials may differ from those when the device is used "off label".
This is
a dark horse, because of the complicated concept of the label defining
the off-label,
but I'll go with it.
If the announcement is made, I'll be posting the results later.
|